Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.02M Sell
282,095
-391,913
-58% -$1.36M ﹤0.01% 5544
2025
Q4
$2.3M Sell
674,008
-189,014
-22% -$917K ﹤0.01% 4844
2025
Q3
$5.86M Sell
863,022
-74,309
-8% -$614K ﹤0.01% 3874
2025
Q2
$12.8M Buy
937,331
+859,444
+1,103% +$8.12M ﹤0.01% 2834
2025
Q1
$424K Sell
77,887
-167,021
-68% -$948K ﹤0.01% 5982
2024
Q4
$1.21M Buy
244,908
+86,785
+55% +$455K ﹤0.01% 5156
2024
Q3
$829K Buy
158,123
+21,654
+16% +$125K ﹤0.01% 4816
2024
Q2
$936K Buy
136,469
+136,306
+83,623% +$1.25M ﹤0.01% 4475
2024
Q1
$1.68K Buy
+163
New +$1.21K ﹤0.01% 8083
2023
Q3
Sell
-975
Closed -$4.24K 9742
2023
Q2
$4.24K Buy
+975
New +$2.17K ﹤0.01% 7554
2023
Q1
Sell
-7,322
Closed -$14.2K 10011
2022
Q4
$14.2K Buy
+7,322
New +$16.4K ﹤0.01% 8099
2022
Q3
Sell
-2,295
Closed -$5K 10657
2022
Q2
$5K Sell
2,295
-2,322
-50% -$5.77K ﹤0.01% 8898
2022
Q1
$16K Buy
4,617
+4,601
+28,756% +$16.3K ﹤0.01% 7740
2021
Q4
$0 Sell
16
-1
-6% -$5 ﹤0.01% 10494
2021
Q3
$0 Buy
+17
New +$145 ﹤0.01% 9826
2021
Q2
Sell
-3,631
Closed -$57K 9614
2021
Q1
$57K Buy
+3,631
New +$65.4K ﹤0.01% 6414

Other funds holding LFMD

UBS Group's LFMD Position: Q1 2026 in Review

UBS Group reduced its LifeMD (LFMD) stake by 58% in Q1 2026, selling an estimated $1.36M and leaving 282,095 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #5544.

UBS Group first reported a position in LFMD in Q1 2021 and has held it in 16 quarters since. The position peaked at $12.8M in Q2 2025. 102 funds tracked by Wall St. Rank hold LFMD as of Q1 2026.

  • UBS Group held 282,095 shares of LifeMD worth $1.02M as of Q1 2026.
  • UBS Group sold 391,913 LifeMD shares in Q1 2026, an estimated $1.36M.
  • LifeMD made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5544 holding.
  • UBS Group first reported a position in LifeMD in Q1 2021 and has held it in 16 quarters since.
  • UBS Group's LifeMD position peaked at $12.8M in Q2 2025.
  • 102 funds tracked by Wall St. Rank held LifeMD as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.